Kept on hold at the FDA, Ipsen scraps a key trial and revamps R&D path for its troubled $1B-plus rare disease drug
After getting slammed by a partial hold on safety fears and flunking a futility test, Ipsen says it has decided to revamp its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
